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1. Search strategy 
 
Different algorithms were designed to search for the relevant literature; the final algorithms 
used for the search in the different datasets up to 30th September 2015, are presented in 
Table S1. 
 
Table S1. Algorithms and databases used for the association between Chagas 
disease and mortality 
 
Database Algorithm Number 
of titles 
Specifications 
used  
PubMed and 
MEDLINE 
((((((mortality) OR death)) OR 
(((((progression) OR outcome) OR follow 
up) OR long term) OR prognos*)) OR 
(((((survival) OR cohort) OR clinical trial) 
OR hazard*) OR prospective))) AND 
((((Chagas[Title/Abstract]) OR 
"Trypanosoma cruzi"[Title/Abstract]) OR 
chagas disease[MeSH Terms]) OR 
American trypanosomiasis) 
 
2,242 Humans only filter 
EMBASE 1. Chagas disease/ or Chagas.mp. 
2. trypanosoma cruzi.mp. or 
Trypanosoma cruzi/ 
3. american trypanosomiasis.mp. 
4. 1 or 2 or 3 
5. mortality/ or mortality.mp. 
6. death.mp. or death/ 
7. 5 or 6 
8. progression.mp. 
9. outcome.mp. 
10. follow-up.mp. 
11. long-term.mp. 
12. prognos*.mp. [mp=title, abstract, 
heading word, drug trade name, original 
title, device manufacturer, drug 
manufacturer, device trade name, 
keyword] 
13. 8 or 9 or 10 or 11 or 12 
14. survival.mp. 
15. cohort.mp. 
16. clinical trial.mp. [mp=title, abstract, 
heading word, drug trade name, original 
title, device manufacturer, drug 
manufacturer, device trade name, 
keyword] 
17. hazard*.mp. [mp=title, abstract, 
heading word, drug trade name, original 
title, device manufacturer, drug 
manufacturer, device trade name, 
keyword] 
18. 14 or 15 or 16 or 17 
19. 7 or 13 or 18 
20. 4 and 19 
2,837 Humans only filter 
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21. prospective.mp. 
22. 14 or 15 or 16 or 17 or 21 
23. 7 or 13 or 22 
24. 4 and 23 
 
Web of Science ((Chagas) OR (Trypanosoma cruzi) OR 
(American trypanosomiasis)) AND 
((mortality) OR (death) OR (survival) OR 
(cohort) OR (clinical trial) OR (hazard) OR 
(prospective) OR (progression) OR 
(outcome) OR (follow up) OR (long term) 
OR (prognos*)) 
 
1,705 Humans only 
Search AND 
(humans OR 
patients OR cases) 
LILACS (tw:((chagas) OR (trypanosoma cruzi) OR 
(enfermedad de chagas) OR (doença de 
chagas) OR (American 
trypanosomiasis))) AND ((tw:(mortality 
OR mortalidad OR mortalidade OR death 
OR muerte OR morte)) OR (tw:( 
Progression OR Progresión OR 
Progressão OR Evolução da cardiopatia 
OR Outcome OR Desenlace* OR 
desfecho*)) OR (tw:( Survival OR 
Supervivencia OR Sobrevivência OR 
Follow-up OR Seguimiento OR 
Seguimento OR prospective OR 
prospective OR longitudinal OR Cohort* 
OR coort* OR prognos* OR pronóstico 
OR prognóstico OR (clinical trial) OR 
(ensayo clínico) OR (ensaio clínico) OR 
hazard)))  
 
2,151 Humans only filter 
TOTAL 8,935  
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2. Quality assessment 
 
The Newcastle–Ottawa Scale (NOS) for quality assessment of cohort studies was used 
(http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Below, we describe the 
criteria used for this scale in the context of our cohort studies on Chagas disease. 
 
Note: A study can be awarded a maximum of one star for each numbered item within the 
selection and outcome categories. A maximum of two stars can be given for comparability 
 
Selection 
 
1) Representativeness of the exposed cohort – Chagas disease patients with clear 
definitions and tests to be classified in one of these clinical groups:  
- Asymptomatic/general population: asymptomatic or minimal ECG findings or from 
the general community (survey) 
- Severe stage: proved by NYHA class III or IV 
- Moderate Stage: proved by NYHA class III or IV 
- All stages: studies with patients in several groups 
 
a) truly representative of the in the community (Star)  
b) somewhat representative of the average in the community (Star) 
c) selected group of users, e.g. nurses, volunteers 
d) no description of the derivation of the cohort 
 
2) Selection of the non-exposed cohort – Non-Chagas disease patients with clear 
definitions and tests to be classified in the same corresponding clinical groups: 
 
a) drawn from the same community as the exposed cohort (Star) 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort 
 
3) Ascertainment of exposure – Chagas disease diagnosis 
a) secure record (e.g. surgical records) (Star) 
b) structured interview (Star) 
c) written self-report 
d) no description 
 
4) Demonstration that outcome of interest (death) was not present at start of study 
a) yes (Star) 
b) no 
 
Comparability 
 
1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for gender and/or age (Star) 
b) study controls for any additional factor (Star) (This criterion could be modified to 
indicate specific control for a second important factor.) 
 
Outcome 
 
1) Assessment of outcome – mortality: clear description of how the outcome was 
investigated 
a) independent blind assessment (Star)  
b) record linkage (Star) 
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c) self-report 
d) no description 
 
2) Cohort was follow up long enough for outcomes to occur – at least 1 year 
a) yes (select an adequate follow up period for outcome of interest) (Star) 
b) no 
 
3) Adequacy of follow-up cohorts 
a) complete follow up - all subjects accounted for (Star)  
b) subjects lost to follow up unlikely to introduce bias - small number lost - > 10% follow 
up, or description provided of those lost) (Star) 
c) follow-up rate < 10% and no description of those lost to follow up 
d) no statement 
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Table S2. Newcastle–Ottawa Scale for quality assessment of the studies included in the meta-analysis 
 
 
First author 
[Reference] 
Year Study 
type 
Follow-up 
type 
1st Star 
 
Represen-
tativeness of 
the studied 
population 
2nd Star 
 
Cohort 
from same 
community 
3rd Star 
 
Ascertain-
ment of 
exposure 
(diagnostic 
test) 
4th Star 
 
Outcome 
is not 
present at 
the 
beginning 
5th Star 
 
Compar-
ability of 
cohorts  
Controlled 
for age 
and sex 
6th Star 
 
Controlled 
for other 
factors 
7th Star 
 
Ascertain-
ment of 
outcome 
(death) 
8th Star
 
(At 
least 1 
year of 
follow 
up) 
9th Star
 
l 
Lost to 
follow-
up 
<10% 
Total 
Stars 
Overall 
Quality 
Coura [1] 1985 Cohort Prospective 1 1 1 1 1 0 1 1 0 7 High 
Pereira [2] 1985 Cohort Prospective 1 1 1 1 1 0 1 1 0 7 High 
Maguire [3] 1987 Cohort Prospective 1 1 1 1 1 0 1 1 1 8 High 
Mota [4] 1990 Cohort/ Prospective 1 1 1 1 1 0 1 1 0 7 High 
Bestetti [5] 1997 Cohort Prospective 1 1 0 1 1 0 0 1 0 5 Moderate 
Pimenta [6] 1999 Cohort Prospective 1 1 1 1 0 0 1 1 0 6 Moderate 
Freitas [7] 2005 Cohort Retrospective 1 1 0 1 0 0 1 1 0 5 Moderate 
De Oliveira [8] 2005 Cohort Prospective 1 1 1 1 0 0 1 0 1 6 Moderate 
De Campos Lopes [9] 2006 Cohort Prospective 1 1 1 1 1 0 1 1 0 7 High 
Heringer-Walther [10] 2006 Cohort Prospective 1 1 0 1 1 1 0 1 0 6 Moderate 
Braga [11] 2008 Cohort Prospective 1 1 0 1 1 1 0 0 0 5 Moderate 
Silva [12] 2008 Cohort Prospective 1 1 0 1 0 0 0 1 1 5 Moderate 
Lima-Costa A [13] 2010 Cohort Prospective 1 1 1 1 1 0 1 1 0 7 High 
Lima-Costa B [14] 2010 Cohort Prospective 1 1 1 1 1 1 1 1 1 9 High 
Pereira-Nunes [15] 2010 Cohort Prospective 1 1 1 1 1 1 1 1 1 9 High 
Issa [16] 2010 Cohort Prospective 1 1 0 1 1 0 0 0 0 4 Low 
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Cardoso [17] 2010 Cohort Prospective 1 1 0 1 1 0 0 1 1 6 Moderate 
Conceição-Souza 
[18] 
2010 Cohort Prospective 1 1 0 1 1 1 0 1 0 6 Moderate 
Cruz [19] 2010 Cohort Prospective 1 1 1 1 1 0 0 1 0 6 Moderate 
Barbosa [20] 2011 Cohort Prospective 1 1 1 1 1 0 0 1 0 6 Moderate 
Ayub-Ferreira [21] 2013 Cohort Prospective 1 1 1 1 1 0 1 1 1 8 High 
Bestetti  [22] 2013 Cohort Prospective 1 1 1 1 1 0 0 1 1 7 High 
Peixoto [23] 2015 Cohort Prospective 1 1 1 1 1 0 1 1 0 7 High 
Traina [24] 2015 Cohort Prospective 1 1 1 1 1 0 1 1 1 8 High 
Sherbuk [25] 2015 Cohort Retrospective 1 1 0 1 0 0 0 1 0 4 Low 
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Fixed-effects model 
 
A fixed-effects model was run for comparison with the random-effects model presented in 
the main text (Fig. 2). The assumption for this model is that the effect size varies between 
studies due to sampling error (error in estimating the effect size). In this case, the weight of 
the study is mainly driven by the sample size. 
 
 
Figure S1. Forest plot of the fixed-effects model for the association between Chagas 
disease and mortality 
 
.
.
.
.
Overall  (I-squared = 67.3%, p = 0.000)
Asymptomatic/General population
Conceição-Souza (2010)
Bestetti (2013)
Pimenta (1999)
Moderate Stage
Sherbuk (2015)
Cruz (2010)
Severe Stage
Heringer-Walther  (2006)
Coura (1985)
Cardoso (2010)
Silva (2008)
Subtotal  (I-squared = 42.8%, p = 0.120)
Mota (1990)
All Stages
Freitas (2005)
ID
Subtotal  (I-squared = 47.1%, p = 0.066)
Braga (2008)
Subtotal  (I-squared = 14.7%, p = 0.320)
Barbosa (2011)
Subtotal  (I-squared = 83.0%, p = 0.000)
Pereira-Nunes (2010)
De Campos (2006)
Bestetti (1997)
Oliveira (2005)
Ayub-Ferreira (2013)
Peixoto  (2015)
Lima-Costa (2010)
Pereira (1985)
Maguire (1987)
Traina (2015)
Lima-Costa B (2010)
Issa  (2010)
Study
1.59 (1.47, 1.71)
1.81 (0.38, 8.71)
2.58 (1.82, 3.66)
2.30 (0.68, 7.78)
6.43 (2.24, 18.43)
1.53 (0.66, 3.56)
1.24 (0.49, 3.12)
2.13 (1.31, 3.46)
1.66 (0.99, 2.79)
1.26 (1.01, 1.58)
1.40 (1.26, 1.56)
1.16 (0.70, 1.90)
1.27 (1.01, 1.58)
RR (95% CI)
2.16 (1.75, 2.66)
1.71 (0.81, 3.59)
1.40 (1.21, 1.62)
2.62 (1.58, 4.35)
2.14 (1.74, 2.63)
1.14 (0.74, 1.78)
1.47 (1.16, 1.87)
4.35 (1.32, 14.35)
1.13 (0.84, 1.54)
4.96 (3.05, 8.06)
1.86 (1.44, 2.40)
1.36 (1.16, 1.60)
3.54 (1.44, 8.70)
0.81 (0.16, 4.02)
3.53 (1.54, 8.07)
1.44 (0.80, 2.58)
1.46 (1.09, 1.96)
100.00
0.27
5.07
0.46
0.41
0.70
0.85
2.60
1.84
8.97
43.12
3.09
12.02
Weight
14.12
1.04
31.74
2.49
11.03
3.71
8.17
0.40
5.09
1.11
7.03
25.25
0.66
0.36
0.45
1.92
6.08
%
  
1.0543 18.4
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3. Heterogeneity analysis 
 
Heterogeneity among studies was measured using Cochran's Q test and I² statistic [26]. 
Cochran's Q is calculated by adding the squared deviations of each study’s estimate from 
the overall meta-analytic estimate, weighting each study’s contribution. For the results of the 
random-effects model presented here and in the main text, those weights account not only 
for the sample size of the particular study, but also for the variance between studies (tau-
squared) within the particular group (i.e. the clinical categories or random effect). The p-
values for this test are obtained by comparing the Q statistic with a chi-square distribution 
with k-1 degrees of freedom (where k is the number of studies). The I² statistic describes the 
percentage of variation across studies that is due to study heterogeneity rather than chance 
(a measure of the degree of inconsistency in the studies’ results), I² = 100% × (Q–df)/Q, 
where Q is the Cochran’s chi-squared statistic and df its degrees of freedom [26]. 
 
The most common guide to interpreting I² is as follows:  
• 0% to 40%: heterogeneity may not be important 
• 30% to 60%: may represent moderate heterogeneity 
• 50% to 90%: may represent substantial heterogeneity 
• 75% to 100%: represents considerable heterogeneity 
 
 
In our analysis, heterogeneity was mostly present in specific clinical groups (Table S3). 
 
 
Table S3. Results of heterogeneity tests in both fixed- and random-effects models  
 
 
 
 
 
Fixed-effects 
model 
Random-effects 
model 
Significant test 
of RR=1 
Significant 
test of RR=1 
Clinical 
classification 
Cochran's 
Q test 
df p-
value 
I² 
statistic 
z p-value 
Tau-
squared 
z p-value
Severe 8.74 5 0.120 42.8% 6.14 <0.001 0.014 4.51 <0.001 
Moderate 13.24 7 0.066 47.1% 7.24 <0.001 0.09 3.12 0.002 
Asymptomatic/ 
general population 
5.86 5 0.320 14.7% 4.56 <0.001 0.014 3.12 0.002 
All stages 23.59 4 0.000 83.0% 7.24 <0.001  3.04 0.002 
Overall 73.37 24 0.000 67.3% 12.08 <0.001 0.079 6.98 <0.001 
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4. Meta-regression 
 
Meta-regression formally compares the differences in event rates across the selected study-
level covariates and estimates the among-study variance, allowing the effects of multiple 
factors to be investigated simultaneously. In meta-regression, the outcome variable is the 
effect estimate, so the regression coefficient obtained will describe how the outcome variable 
(RR in this case) changes with a unit increase in the explanatory variable (the potential effect 
modifier) [27]. 
 
For this study a meta-regression was used to test the impact of potential effect modifiers, 
namely, clinical characteristics, follow-up time, starting year of the study, and proportion of 
men, on effect size of the RR (Table S4). 
 
Table S4. Meta-regression on the RR effect of Chagas on mortality (measured as 
logRR). 
 
logRR Coefficient Standard 
Error 
t p>|t| 95% Confidence 
Interval 
Clinical 
classification 0.32 0.18 1.76 0.10 –0.07 0.70
Star year of the 
study 0.01 0.01 0.74 0.47 –0.02 0.04
Proportion of men –2.11 1.33 1.59 0.14 –4.96 0.74
Location –0.22 0.27 0.83 0.42 –0.80 0.35
Constant –19.47 28.89 0.67 0.51 –81.44 42.49
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5. Publication bias 
 
To explore the potential impact of publication bias on our estimates of excess mortality, we 
used a trim-and-fill technique to re-estimate the effect incorporating hypothetically missing 
studies [28]. The results are presented in Fig. S3 and Fig. S4. 
 
Figure S2. Funnel plot of trim-and-fill technique for re-estimating the effect size  
 
 
 
Filled funnel plot with pseudo 95% confidence limits
 
th
et
a,
 fi
lle
d
s.e. of: theta, filled
0 .2 .4 .6 .8
-2
-1
0
1
2
 
On the left axis the log(RR) (theta) from each study is plotted against its corresponding 
standard error (s.e.). Circles represent the studies included in the meta-analysis and the 
squares represent the hypothetically missing studies. Lines represent pseudo 95% 
confidence limits for the re-estimate using the ‘filled’ studies. 
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Figure S3. Forest plot for the trim-and-fill technique  
 
 
theta, filled
.105776 18.4273
 Combined
 Sherbuk (2015)
 Ayub-Ferreira (2013)
 Bestetti (1997)
 Pereira (1985)
 Traina (2015)
 Barbosa (2011)
 Bestetti (2013)
 Pimenta (1999)
 Coura (1985)
 Peixoto  (2015)
 Conceição-Souza (2010
 Braga (2008)
 Cardoso (2010)
 Cruz (2010)
 De Campos (2006)
 Issa  (2010)
 Lima-Costa B (2010)
 Lima-Costa (2010)
 Freitas (2005)
 Silva (2008)
 Heringer-Walther  (20
 Mota (1990)
 Pereira-Nunes (2010)
 Oliveira (2005)
 Maguire (1987)
 fill 7
 fill 6
 fill 5
 fill 4
 fill 3
 fill 2
 fill 1
 
The effect estimate (RR, theta) from the studies included in the meta-analysis (with authors 
and years) and the hypothetically missing studies (fill 1, 2, 3, 4, 5, 6, 7) are plotted. The 
missing studies would have a bias towards lower excess mortality. 
 
The magnitude of the RR re-estimated after applying the Trim and Fill technique (as a 
random-effects model) is 1.42 (95%CI 1.19–1.70). 
 
This result indicates that the RR estimate and its uncertainty bounds obtained from the 
meta-analysis are not strongly affected by missing studies. 
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6. Sensitivity analysis 
 
To identify potential outliers and assess their potential impact on the results of the meta-
analysis, we re-evaluated the (fixed-effects) model after removing each study one at a time. 
The original RR estimate was compared to that obtained after omitting each study (Figure 
S4).  
 
Figure S4. Sensitivity analysis for the fixed-effects model based on omitting one study 
at a time 
 
 
  1.39   1.54  1.43   1.66   1.73
 Oliveira (2005)
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 Traina (2015)
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 Maguire (1987)
 Mota (1990)
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 Study ommited
 Meta-analysis fixed-effects estimates (exponential form)
 
 
 
The re-estimated effect size (RR, open circles) and its 95% confidence interval (dotted 
horizontal lines) are plotted on the horizontal axis after removing each study in turn (left 
axis). Values and 95%CI were hardly affected by removing any single study, indicating no 
evidence of outliers in the studies selected for meta-analysis. 
 
Figure S5 presents the results of restricting the analysis to only those ranked as ‘high quality’ 
studies (see Table S2). This sub-analysis was conducted to obtain robust estimates of 
excess mortality among clinical categories, and to assess the impact on our results of study 
quality. The results of the meta-analysis conducted using only high quality papers were very 
similar to those of the meta-analysis presented in the main text, indicating that study quality 
did not strongly influence the results. 
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Fig. S5. Forest plot of the fixed-effects model for the association between Chagas 
disease and mortality including only “high quality” studies 
 
 
 
 
 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 77.5%, p = 0.000)
Subtotal  (I-squared = 22.8%, p = 0.269)
Mota (1990)
Ayub-Ferreira (2013)
Issa  (2010)
All Stages
Maguire (1987)
Study
Asymptomatic/General population
Borges-Pereira (1985)
Heringer (2006)
Lima-Costa B (2010)
Bestetti (2013)
ID
Coura (1985)
Traina (2015)
Subtotal  (I-squared = 0.0%, p = 0.487)
Subtotal  (I-squared = 83.0%, p = 0.000)
Lima-Costa (2010)
Moderate Stage
Sherbuk (2015)
2.07 (1.54, 2.78)
1.40 (1.10, 1.80)
1.16 (0.70, 1.90)
4.96 (3.05, 8.06)
1.46 (1.09, 1.96)
0.81 (0.16, 4.02)
3.54 (1.44, 8.70)
1.24 (0.49, 3.12)
1.44 (0.80, 2.58)
2.58 (1.82, 3.66)
RR (95% CI)
2.13 (1.31, 3.46)
3.53 (1.54, 8.07)
2.70 (1.96, 3.73)
2.52 (1.39, 4.58)
1.36 (1.16, 1.60)
6.43 (2.24, 18.43)
100.00
39.98
9.68
9.81
11.80
2.75
%
6.00
5.81
8.76
11.23
Weight
9.83
6.56
17.79
42.23
12.80
4.98
  
1.0543 18.4
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